{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:12:10Z","timestamp":1788556330766,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pathology Informatics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jpi.2026.100688","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:27:23Z","timestamp":1782343643000},"page":"100688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Automated measurement of CD8+ T-cell distribution at the tumor epithelial\u2013stromal interface is associated with NSCLC immunotherapy benefit and transcriptomic pathways"],"prefix":"10.1016","volume":"22","author":[{"given":"Patrick","family":"Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Kolster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Koeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Giltnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata S.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niha","family":"Beig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barzin Y.","family":"Nabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velimir","family":"Gayevskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ruderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleopatra","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpi.2026.100688_bb0005","article-title":"Immune checkpoint inhibitors for lung cancer treatment: a review","volume":"9","author":"Onoi","year":"2020","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jpi.2026.100688_bb0010","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jpi.2026.100688_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpi.2026.100688_bb0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jpi.2026.100688_bb0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpi.2026.100688_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.jpi.2026.100688_bb0035","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jpi.2026.100688_bb0040","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1078-0432.CCR-21-3844","article-title":"FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced\/metastatic PD-L1 high NSCLC","volume":"28","author":"Akinboro","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpi.2026.100688_bb0045","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","volume":"5","author":"Prince","year":"2021","journal-title":"JCO Precis. Oncol"},{"key":"10.1016\/j.jpi.2026.100688_bb0050","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.21873\/anticanres.12662","article-title":"Heterogeneity of PD-L1 expression and relationship with biology of NSCLC","volume":"38","author":"Bassanelli","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jpi.2026.100688_bb0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-016-9652-y","article-title":"Next generation predictive biomarkers for immune checkpoint inhibition","volume":"36","author":"Khagi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jpi.2026.100688_bb0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0070","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jpi.2026.100688_bb0080","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/path.6155","article-title":"Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"260","author":"Thagaard","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.jpi.2026.100688_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594609","article-title":"Cytokine and chemokine signals of T-cell exclusion in tumors","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpi.2026.100688_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/25764","article-title":"Three-dimensional segregation of supramolecular activation clusters in T cells","volume":"395","author":"Monks","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jpi.2026.100688_bb0095","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1038\/s41467-021-25282-3","article-title":"Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity","volume":"12","author":"Weigelin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jpi.2026.100688_bb0100","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpi.2026.100688_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpi.2026.100688_bb0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jpi.2026.100688_bb0115","article-title":"Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy","author":"Li","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.jpi.2026.100688_bb0120","article-title":"Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors","volume":"8","author":"Wang","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.jpi.2026.100688_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003833","article-title":"Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities","volume":"10","author":"Azarianpour","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0130","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1038\/s41467-020-19408-2","article-title":"Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer","volume":"11","author":"Desbois","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jpi.2026.100688_bb0135","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2589-7500(24)00116-X","article-title":"A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK\/ANZ DCIS trial","volume":"6","author":"Li","year":"2024","journal-title":"Lancet Digit Heal"},{"key":"10.1016\/j.jpi.2026.100688_bb0140","series-title":"2009 IEEE Int. Symp. Biomed. Imaging: Nano Macro","first-page":"1107","article-title":"A method for normalizing histology slides for quantitative analysis","author":"Macenko","year":"2009"},{"key":"10.1016\/j.jpi.2026.100688_bb0145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","article-title":"Cellpose: a generalist algorithm for cellular segmentation","volume":"18","author":"Stringer","year":"2020","journal-title":"Nat Methods"},{"key":"10.1016\/j.jpi.2026.100688_bb0150","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41592-022-01663-4","article-title":"Cellpose 2.0: how to train your own model","volume":"19","author":"Pachitariu","year":"2022","journal-title":"Nat Methods"},{"key":"10.1016\/j.jpi.2026.100688_bb0155","series-title":"Graphics Gems VIII: Image Processing","first-page":"474","author":"Zuiderveld","year":"1994"},{"key":"10.1016\/j.jpi.2026.100688_bb0160","doi-asserted-by":"crossref","DOI":"10.1117\/1.3275471","article-title":"Is there a difference between T- and B-lymphocyte morphology?","volume":"14","author":"Strokotov","year":"2009","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.jpi.2026.100688_bb0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2020.10.017","article-title":"Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non\u2013small cell lung cancer treated with immunotherapy","volume":"145","author":"Gataa","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0170","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jpi.2026.100688_bb0175","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpi.2026.100688_bb0180","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1093\/nar\/gkt660","article-title":"Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations","volume":"41","author":"Yaari","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jpi.2026.100688_bb0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jpi.2026.100688_bb0190","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.jpi.2026.100688_bb0195","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.jpi.2026.100688_bb0200","doi-asserted-by":"crossref","first-page":"73068","DOI":"10.18632\/oncotarget.12230","article-title":"The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpi.2026.100688_bb0205","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.18632\/oncotarget.24283","article-title":"Analysis of response rate with ANTI PD1\/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials","volume":"9","author":"Carretero-Gonz\u00e1lez","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpi.2026.100688_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpi.2026.100688_bb0215","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jpi.2026.100688_bb0220","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S1470-2045(19)30154-8","article-title":"Digital pathology and artificial intelligence","volume":"20","author":"Niazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpi.2026.100688_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41571-025-00991-6","article-title":"Artificial intelligence in digital pathology \u2014 time for a reality check","volume":"22","author":"Aggarwal","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jpi.2026.100688_bb0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0235","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.ajpath.2020.01.018","article-title":"Immunogradient indicators for antitumor response assessment by automated tumor-stroma interface zone detection","volume":"190","author":"Rasmusson","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jpi.2026.100688_bb0240","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/cancers15041205","article-title":"CD8+ cell density gradient across the tumor epithelium\u2013stromal interface of non-muscle invasive papillary urothelial carcinoma predicts recurrence-free survival after BCG immunotherapy","volume":"15","author":"Drachneris","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jpi.2026.100688_bb0245","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41374-021-00653-y","article-title":"Establishing standardized immune phenotyping of metastatic melanoma by digital pathology","volume":"101","author":"Sobottka","year":"2021","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"10.1016\/j.jpi.2026.100688_bb0250","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jpi.2026.100688_bb0255","article-title":"Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges","volume":"4","author":"Chen","year":"2025","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.jpi.2026.100688_bb0260","article-title":"What clinicians want: contextualizing explainable machine learning for clinical end use","author":"Tonekaboni","year":"2019","journal-title":"arXiv"}],"container-title":["Journal of Pathology Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2153353926001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2153353926001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:16:19Z","timestamp":1788552979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2153353926001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["S2153353926001471"],"URL":"https:\/\/doi.org\/10.1016\/j.jpi.2026.100688","relation":{},"ISSN":["2153-3539"],"issn-type":[{"value":"2153-3539","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Automated measurement of CD8+ T-cell distribution at the tumor epithelial\u2013stromal interface is associated with NSCLC immunotherapy benefit and transcriptomic pathways","name":"articletitle","label":"Article Title"},{"value":"Journal of Pathology Informatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpi.2026.100688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Association for Pathology Informatics.","name":"copyright","label":"Copyright"}],"article-number":"100688"}}